Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why The Medicines Company Jumped 60% in November

By Cory Renauer - Dec 3, 2019 at 6:37AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Terrific clinical trial data followed by a $9.7 billion buyout offer gave investors lots to be thankful for.

What happened

Shares of The Medicines Company ( MDCO ), a post-commercial biotech, soared 60.4% in November, according to data from S&P Global Market Intelligence. Encouraging pivotal trial results last month inspired Novartis ( NVS -0.28% ) to make a buyout offer for The Medicines Company for $9.7 billion in cash.

So what

Back in 2013, The Medicines Company gave Alnylam Pharmaceuticals $25 million up front for rights to inclisiran, an RNA drug that interferes with the production of a protein that limits the liver's ability to absorb low-density lipoprotein cholesterol (LDL-C). After lots of positive data, The Medicines Company felt confident enough about inclisiran that it sold off all its commercial-stage assets to attract a buyer earlier this year.

Person drawing an upward-sloping arrow with a finger.

Image source: Getty Images.

The Medicines Company stock took flight after investors learned inclisiran helped reduce LDL-C by half, or better, for different groups of difficult-to-treat patients. A week later, Novartis agreed to buy The Medicines Company for a steep premium.

Now what

The Medicines Company's return on its inclisiran investment is the stuff of legends, but Novartis could have a tough time squeezing $9.7 billion from the same drug in the commercial stage. Expensive new cholesterol drugs have received lots of pushback from insurers when it comes to large populations. Inclisiran will probably be used to treat a small number of patients with inherited hypercholesterolemia, but reaching tens of millions of people with atherosclerotic cardiovascular disease is another story.

Inclisiran offers the convenience of twice-yearly administration, but it's also an infusion that requires help from healthcare providers instead of a simple injector pen that patients operate themselves. Praluent and Repatha are easily injected once or twice a month and they aim for the same target as inclisiran, plus they're only a little less effective.

Repatha's doing better on the market than Praluent, but sales of the drug only reached an annualized $672 million in the third quarter after four years of spotty sales. Five years from now I'll be surprised if Novartis can do any better with inclisiran if it earns approval.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

The Medicines Company Stock Quote
The Medicines Company
Novartis AG Stock Quote
Novartis AG
$79.73 (-0.28%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.